Mark A. Frye, MD

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota

46Articles
173.1KReads
1997–2026Active
161Collaborators
2.3KCitations

Publications

Psychotherapy, Pharmacotherapy, and Neuromodulatory Interventions in Operational Definitions of TRD: Reply to De Oliveira Reis et al

Letter to the Editor

Psychotherapy, Pharmacotherapy, and Neuromodulatory Interventions in Operational Definitions of TRD: Reply to De Oliveira Reis et al

August 19, 2026

Marques et al reply to commentary on their consensus-based recommendations for treatment-resistant depression.

Matheus G. Marques, Mark A. Frye, Balwinder Singh

Next-Step Treatment Options for Treatment-Resistant Depression

Consensus Statement

Next-Step Treatment Options for Treatment-Resistant Depression

January 21, 2026

Strong consensus emerged for augmentation with second-generation antipsychotics, TMS, and ketamine/esketamine in the base vignette. Preferences shifted to include non-augmentative antidepressants and ECT based on patient characteristics.

Matheus G. Marques, Aysegul Özerdem, Simon Kung, et al

Ketamine Reduces Suicidality Associated ED Use in Patients With Treatment-Resistant Depression

Original Research

Ketamine Reduces Suicidality Associated ED Use in Patients With Treatment-Resistant Depression

September 17, 2025

After the acute phase of ketamine treatment, ED visits for suicidal ideation decreased by 84%, and total ED visits for suicidality decreased by 63%.

Liliana Patarroyo-Rodriguez, Vanessa K. Pazdernik, Jennifer L. Vande Voort, et al

SSRI Discontinuation and AUD Relapse

Case Report

SSRI Discontinuation and AUD Relapse

August 26, 2024

A man with AUD achieves sobriety on treatment with an SSRI and naltrexone, but then stops taking the SSRI to participate in a psilocybin “ceremony.” What factors contributed to...

Mark A. Frye, Balwinder Singh, Scott A. Breitinger, et al

Ketamine vs Esketamine for TRD

Original Research

Ketamine vs Esketamine for TRD

February 1, 2023

Are ketamine and esketamine equally efficacious? This observational study compares the efficacy of subanesthetic intravenous ketamine with that of intranasal esketamine for treatment-resistant depression in a real-world clinical setting.

Balwinder Singh, Simon Kung, Vanessa Pazdernik, et al

Review Article

Exercise, Yoga, and Tai Chi for Depression

December 31, 2020

Exercise, yoga, and tai chi are commonly used complementary approaches for health and wellness. This review aims to synthesize the evidence for exercise, yoga, and tai chi in the...

Mark A. Frye, Balwinder Singh, Ashok Seshadri, et al

Original Research

Stress Management and Resiliency Training for Depression

April 30, 2020

Stress is associated with the onset, maintenance, and recurrence of depression. This study aimed to investigate the feasibility of stress management and resiliency training for enhancing resiliency in a...

Mark A. Frye, Jose A. Rico, Jr, Simon Kung, et al

Letter to the Editor

BMI and Remission in Depressed Patients Receiving IV Ketamine

November 12, 2019

Few studies have evaluated optimal dosing of intravenous (IV) ketamine for treatment-resistant depression (TRD). This report analyzes data from previous studies of IV ketamine to assess the association between...

Mark A. Frye, Keith G. Rasmussen, William V. Bobo, et al

Original Research

DSM-IV vs DSM-5: Effect on Bipolar Disorder Diagnosis

October 29, 2019

Since 2013, when DSM-5 was published, a third of the patients previously diagnosed with bipolar disorder no longer qualify as having the disorder. So what does this say about...

Mark A. Frye, Paul E. Keck, Jr., Susan L. McElroy, et al

Original Research

Genetics of Early-Onset Bipolar Disorder

February 14, 2017

Early-onset bipolar disorder may represent a distinct phenotype with greater severity, but the genetics of it are still poorly understood. This study used candidate genetic risk score analysis to...

Karen Dineen Wagner, Mark A. Frye, Paul E. Croarkin, et al

Original Research

Age at Onset of Bipolar Disorder

October 26, 2016

Read this article to learn whether age of onset of bipolar disorder or psychiatric illness is due to demographics or family psychiatric history.

Lori L. Altshuler, Mark A. Frye, Susan L. McElroy, et al

Original Research

Evidence of a Cohort Effect in Bipolar

August 24, 2016

Read an article exploring further evidence of the cohort effect for earlier age at onset of bipolar disorder and greater burden of psychiatric disorders.

Lori L. Altshuler, Mark A. Frye, Susan L. McElroy, et al

1 2 3 4 »

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.